Multicell Technologies Inc
OTC:MCET
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
M
|
Multicell Technologies Inc
OTC:MCET
|
5k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.2B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Multicell Technologies Inc
Glance View
MultiCell Technologies, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Woonsocket, Rhode Island. The firm and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The firm's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
Over the last 0 months, Multicell Technologies Inc’s Gross Margin has decreased from 5.7% to 5.7%. During this period, it reached a low of 5.7% on Oct 1, 2015 and a high of 5.7% on Oct 1, 2015.
